BioCryst Pharmaceuticals, Inc. Share Price
Equities
BCRX
US09058V1035
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.16 USD | 0.00% | -6.09% | -30.55% |
Sales 2024 * | 395M 31.63B | Sales 2025 * | 484M 38.78B | Capitalization | 858M 68.71B |
---|---|---|---|---|---|
Net income 2024 * | -128M -10.25B | Net income 2025 * | -65M -5.2B | EV / Sales 2024 * | 2.76 x |
Net Debt 2024 * | 234M 18.73B | Net Debt 2025 * | 259M 20.71B | EV / Sales 2025 * | 2.31 x |
P/E ratio 2024 * |
-6.6
x | P/E ratio 2025 * |
-12
x | Employees | 536 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.83% |
Latest transcript on BioCryst Pharmaceuticals, Inc.
1 week | -6.09% | ||
Current month | -18.11% | ||
1 month | -16.97% | ||
3 months | -23.53% | ||
6 months | -23.81% | ||
Current year | -30.55% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 31/12/06 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 01/04/20 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 26/02/20 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 31/12/06 |
Director/Board Member | 60 | 25/07/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 0 M€ | 0.00% | - | |
0.20% | 0 M€ | 0.00% | - | |
0.18% | 1,026 M€ | +6.95% | - | |
0.13% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 4.16 | 0.00% | 2,310,948 |
25/04/24 | 4.16 | -1.19% | 2,735,562 |
24/04/24 | 4.21 | -3.88% | 4,409,981 |
23/04/24 | 4.38 | -0.68% | 4,236,664 |
22/04/24 | 4.41 | -0.45% | 2,557,483 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.55% | 858M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BCRX Stock